If you have been reading about Cardarine and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-30. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
==== Anesthesia awareness ==== Thiopental is a rapid and effective drug for inducing unconsciousness, since it causes loss of consciousness upon a single circulation through the brain due to its high lipophilicity. Only a few other drugs, such as methohexital, etomidate, or propofol, have the capability to induce anesthesia so rapidly. (Narcotics such as fentanyl are inadequate as induction agents for anesthesia.) Supporters argue that since the thiopental is given at a much higher dose than for medically induced coma protocols, it is effectively impossible for the condemned to wake up. Anesthesia awareness occurs when general anesthesia is inadequately maintained, for a number of reasons. Typically, anesthesia is 'induced' with an intravenous drug but 'maintained' with an inhaled anesthetic given by the anesthesiologist or nurse-anesthetist (note that there are several other methods for safely and effectively maintaining anesthesia). Barbiturates are used only for induction of anesthesia, and although these drugs rapidly and reliably induce anesthesia, they wear off quickly. A neuromuscular-blocking drug may then be given to cause paralysis, which facilitates intubation, although this is not always required. The anesthesiologist or nurse anesthetist is responsible for ensuring that the maintenance technique (typically inhalational) is started soon after induction to prevent the patient from waking up. General anesthesia is not maintained with barbiturate drugs because they are so short-acting.
APPI has also been effectively applied for ambient ionization applications lending itself to several practical configurations. One configuration termed desorption APPI (DAPPI) was developed by Haapala et al. and is pictured in the figure here. This device has been applied to the analysis of drugs of abuse in various solid phases, drug metabolites and steroids in urine, pesticides in plant material, etc. APPI has also been interfaced to a DART (direct analysis in real time) source and shown for non-polar compounds such as steroids and pesticides to enhance signal by up to an order of magnitude for N2 flow, which is preferred for DART because it is significantly cheaper and easier to generate then the higher performing use of He. Commercial APPI sources have also been adapted to accept an insertable sampling probe that can deliver or liquid or solid sample to the nebulizer for vaporization and ionization. This configuration is similar to atmospheric solid analysis probe (ASAP) that is based on the use of APCI and therefore is referred to as APPI-ASAP. The benefits of APPI-ASAP vs. APCI-ASAP are similar to those observed in LC/MS, namely higher sensitivity to lower polarity compounds and less background signal for samples in complex matrices. Though ambient ionization has experienced a renaissance in the last decades, it has been used in the security industry for many decades, for example in swab detections at airports.
On September 30, 2009, the NNSA announced that about two thirds of the special nuclear material (e.g., plutonium) at LLNL requiring the highest level of security protection had been removed from LLNL. The move was part of NNSA's efforts initiated in October 2006 to consolidate special nuclear material at five sites by 2012, with significantly reduced square footage at those sites by 2017. The federally mandated project intended to improve security and reduce security costs, as part of NNSA's overall effort to transform the Cold War era "nuclear weapons" enterprise into a 21st-century "nuclear security" enterprise. The original date to remove all high-security nuclear material from LLNL, based on equipment capability and capacity, was 2014. NNSA and LLNL then developed a timeline to remove this material earlier, and accelerated the completion date to 2012.
5-Hydroxytryptophan (5-HTP), used medically as oxitriptan, is a naturally occurring amino acid and chemical precursor as well as a metabolic intermediate in the biosynthesis of the neurotransmitter serotonin. 5-HTP can be manufactured and used as a drug and supplement with the INNTooltip International Nonproprietary Name oxitriptan. Brand names include Cincofarm, Levothym, Levotonine, Oxyfan, Telesol, Tript-OH, and Triptum. As a drug, it is used in the treatment of depression and for certain other indications. 5-HTP is produced from the amino acid tryptophan through the action of the enzyme tryptophan hydroxylase. Tryptophan hydroxylase is one of the biopterin-dependent aromatic amino acid hydroxylases. Production of 5-HTP is the rate-limiting step in 5-HT (serotonin) synthesis. 5-HTP is normally rapidly converted to 5-HT by amino acid decarboxylase.
Sources: en.wikipedia.org
Thorium is much more similar to the transition metals zirconium and hafnium than to cerium in its ionization energies and redox potentials, and hence also in its chemistry: this transition-metal-like behaviour is the norm in the first half of the actinide series, from actinium to americium.
Sitagliptin/metformin, sold under the brand name Janumet among others, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It may be used in those whose blood sugar is not controlled with metformin and a sulfonylurea. It is taken by mouth. Common side effects include diarrhea, headache, and upper respiratory tract infections. Serious side effects may include lactic acidosis, pancreatitis, low blood sugar, heart failure, joint pain, and allergic reactions. It has not been properly studied in women who are pregnant or breastfeeding. It contains sitagliptin (a dipeptidyl peptidase-4 inhibitor) and metformin (a biguanide). The combination was approved for medical use in the United States in 2007. In 2022, it was the 182nd most commonly prescribed medication in the United States, with more than 2 million prescriptions. It is available as a generic medication.
Senator Andy Kim of New Jersey described it as "unhinged and embarrassing", and Chris Murphy, a member of the Senate Foreign Affairs Committee, as "the ramblings of a man who has lost touch with reality". Vin Gupta, the medical analyst for NBC News, said the letter "crossed a line of proper adult behavior" and should have had a "more thorough public assessment of his neurological fitness," stating that Trump's behavior including his letter to Støre could be signs of early Alzheimer's or frontotemporal dementia. On January 21, 2026, while speaking in Davos, Trump would at least four times refer to Greenland as "Iceland." On January 22, 2026, Trump spoke before world leaders at a summit in Davos, and photographers captured photos of him with a large bruise on his left hand, unlike the bruise on his other hand, which the administration had to address publicly. Trump has publicly attributed the bruising to shaking hands, but he is accustomed to using his right hand, not his left. On January 29, 2026, shortly after the signing of Executive Order 14379[ws] "Addressing Addiction through the Great American Recovery Initiative", Trump and his cabinet dismissed news reporters from the Oval Office without an interview. Some social media users, including Rebekah Jones, speculated that the press conference ended abruptly due to Trump defecating himself. These accusations cited an unidentified sound and apparent reactions from Pam Bondi and Doug Burgum's wife Kathryn heard and seen in Forbes's live coverage.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.